modelB05XA14
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | SodiumGlycerophosphate | |
| ATC code: | B05XA14 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 60 | mL/min |
| other parameters in model implementation | ||
Sodium glycerophosphate is an inorganic phosphate salt commonly used as a source of phosphate in intravenous nutrition (parenteral nutrition) for patients who cannot obtain sufficient nutrition orally or enterally. It provides both sodium and phosphate ions, and is indicated to prevent or treat hypophosphatemia, primarily in hospitalized or critically ill patients. It is not widely approved as a standalone pharmaceutical for oral administration, but is a well-established component of parenteral nutrition regimens.
Pharmacokinetics
Pharmacokinetic profile estimated for healthy adult patients receiving intravenous infusion for parenteral nutrition. No human PK data was found in peer-reviewed publications; estimates derived from known phosphate salt kinetics and parenteral administration.
References
Topp, H, et al., & Rothenburger, M (2011). Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics. Pharmacology 88(3-4) 193–200. DOI:10.1159/000331341 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21986180
Topp, H, et al., & Rothenburger, M (2011). Glycerophosphate does not interact with components of parenteral nutrition. Pharmacology 88(1-2) 114–120. DOI:10.1159/000330066 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21865768
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)